



## Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment

January 16, 2020 at 8:00 AM EST

*Together, Charles River and Fios Genomics aim to accelerate preclinical discovery and development by turning complex data into actionable information*

WILMINGTON, Mass. & EDINBURGH, Scotland--(BUSINESS WIRE)--Jan. 16, 2020-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with [Fios Genomics](#), a leading provider of bioinformatics data analysis services.

Access to high quality, transparent bioinformatics presents a challenge for many drug development teams. Compiling disparate, complex data file types into single datasets for interpretation requires a rigorous assessment of data quality, as well as an analytical approach that emphasizes biological relevance and the assessment of statistical significance.

Through this partnership, Charles River clients will have access to Fios Genomics' expertise in bioinformatics, statistics and biology to assist in the sourcing and analysis of the high-dimensional, multi-variant datasets associated with drug development including microarrays, next-generation sequencing (NGS), proteomics, metabolomics and epigenetics as well as the associated meta-data.

The biologically-relevant insights revealed by the team at Fios Genomics, combined with Charles River's streamlined integrated drug discovery and development platform and the scientific expertise of both organizations, will enable Charles River clients to make more data-driven decisions about their programs, improving both confidence and speed.

### Approved Quotes

- "The explosion in -omics data has been a boon for the drug discovery industry, but analysis and interpretation of these datasets are challenging. Through our partnership with Fios Genomics, Charles River clients will have greater access to the special combination of skills in bioinformatics, statistics and biology required to obtain meaningful information from their data." –Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River
- "Our approach to bioinformatics at Fios Genomics is to look beyond algorithms and statistics and understand that biological relevance and statistical significance are not necessarily the same thing. Bioinformatics is about biology, outcome and pathways, and by partnering with Charles River, we can help more researchers make data-driven decisions about their programs that are grounded in biological insights." –Sarah Lynagh, PhD, Chief Executive Officer at Fios Genomics

### About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit [www.criver.com](http://www.criver.com).

### About Fios Genomics

Fios Genomics provide a wide range of bioinformatics analysis services, supporting drug discovery and development and applied research across all species. Using the best in class tools and methods, Fios provide a functional and interactive reporting architecture, allowing scientists to fully explore their data. We can analyse 'omics data in combination with other outputs from experiments or trials such as imaging data and clinical information. This helps to build up the data picture while ensuring that a robust analysis is delivered. To learn more about our capabilities, visit [www.fiosgenomics.com](http://www.fiosgenomics.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200116005432/en/>

Source: Charles River Laboratories International, Inc.

### Investor Contact:

Todd Spencer  
Corporate Vice President, Investor Relations  
781-222-6455  
[todd.spencer@crl.com](mailto:todd.spencer@crl.com)

### Media Contact:

Charles River  
Amy Cianciaruso  
Corporate Vice President, Public Relations  
781-222-6168  
[amy.cianciaruso@crl.com](mailto:amy.cianciaruso@crl.com)

*Fios Genomics*  
Callum Spreng  
Managing Director, Spreng Thomson  
+44 (0)141 548 5191  
[Callum@sprengthomson.com](mailto:Callum@sprengthomson.com)